Icerol-SR Capsule is a combination pharmaceutical formulation containing Levosulpiride 75 mg and Rabeprazole 20 mg, designed for the management of gastrointestinal disorders. Levosulpiride, a selective dopamine D2 receptor antagonist, exhibits prokinetic and antiemetic properties by enhancing gastric motility and accelerating gastric emptying, thereby alleviating symptoms such as nausea, vomiting, bloating, and dyspepsia. Rabeprazole, a proton pump inhibitor, suppresses gastric acid secretion by irreversibly inhibiting the H+/K+ ATPase enzyme system in gastric parietal cells, promoting mucosal healing and providing symptomatic relief in acid-related disorders. The synergistic action of these agents makes Icerol-SR effective in the treatment of gastroesophageal reflux disease (GERD), functional dyspepsia, and peptic ulcer disease. It is indicated for patients experiencing upper gastrointestinal symptoms associated with delayed gastric emptying and acid hypersecretion. Icerol-SR should be administered as prescribed by a healthcare professional, with caution advised in individuals with known hypersensitivity to either component or those with severe hepatic or renal impairment. Common adverse effects may include headache, dizziness, and mild gastrointestinal disturbances. Patient adherence to dosage and duration is essential for optimal therapeutic outcomes.